Cellumed Co. Ltd Total Liabilities
Cellumed Co. Ltd total liabilities. Based on the latest financial reports, Cellumed Co. Ltd (049180) has total liabilities worth ₩55.10 Billion KRW (≈ $37.34 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Cellumed Co. Ltd's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Cellumed Co. Ltd (2008–2024)
Total liabilities of Cellumed Co. Ltd from 2008 to 2024. This chart illustrates how Cellumed Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 049180 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Cellumed Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Cellumed Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Batavia Prosperindo Finance
JK:BPFI
|
Indonesia | Rp1.96 Trillion |
|
Ihlas Haber Ajansi AS
IS:IHAAS
|
Turkey | TL168.59 Million |
|
Insung Information Co. Ltd
KQ:033230
|
Korea | ₩114.03 Billion |
|
PanGen Biotech Inc
KQ:222110
|
Korea | ₩2.74 Billion |
|
STG International Ltd
TA:STG
|
Israel | ILA46.77 Million |
|
Eastern Star Real Estate Public Company Limited
BK:ESTAR
|
Thailand | ฿2.20 Billion |
|
JERSEY OIL+GAS PLC LS-01
F:TPC1
|
Germany | €147.08K |
|
Avonmore Capital & Management Services Limited
NSE:AVONMORE
|
India | Rs757.90 Million |
Liability Composition Analysis (2008–2024)
This chart breaks down Cellumed Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Cellumed Co. Ltd asset portfolio.
Liquidity & Leverage Metrics
Cellumed Co. Ltd Total Liabilities Ratios Explained
Cellumed Co. Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.77 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cellumed Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cellumed Co. Ltd (2008–2024)
The table below shows the annual total liabilities of Cellumed Co. Ltd from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩61.45 Billion ≈ $41.64 Million |
+41.41% |
| 2023-12-31 | ₩43.45 Billion ≈ $29.45 Million |
+10.54% |
| 2022-12-31 | ₩39.31 Billion ≈ $26.64 Million |
-18.75% |
| 2021-12-31 | ₩48.38 Billion ≈ $32.79 Million |
+13.31% |
| 2020-12-31 | ₩42.70 Billion ≈ $28.94 Million |
-28.59% |
| 2019-12-31 | ₩59.80 Billion ≈ $40.53 Million |
+125.12% |
| 2018-12-31 | ₩26.56 Billion ≈ $18.00 Million |
-4.11% |
| 2017-12-31 | ₩27.70 Billion ≈ $18.77 Million |
+19.24% |
| 2016-12-31 | ₩23.23 Billion ≈ $15.74 Million |
-42.97% |
| 2015-12-31 | ₩40.73 Billion ≈ $27.60 Million |
+54.34% |
| 2014-12-31 | ₩26.39 Billion ≈ $17.89 Million |
-7.64% |
| 2013-12-31 | ₩28.57 Billion ≈ $19.36 Million |
-15.55% |
| 2012-12-31 | ₩33.84 Billion ≈ $22.93 Million |
-28.76% |
| 2011-12-31 | ₩47.49 Billion ≈ $32.18 Million |
+238.53% |
| 2008-12-31 | ₩14.03 Billion ≈ $9.51 Million |
-- |
About Cellumed Co. Ltd
Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. The company offers CLnZyme, a mRNA enzyme; cosmeceuticals, such as FGF7 for skin regeneration and TGFß-1 for tissue regeneration; and electric motorcycles. It provides tissue bank products, such as celluderm powder, ultra, and HD implant for the skin; patellar tendon hemi… Read more